Mounjaro , also known as tirzepatide , is a dual agonist compound that targets both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Trulicity for use in the UK, and it is available on NHS prescription for patients with type 2 diabetes who meet specific clinical criteria outlined in NICE guidance (NG28)
The lawsuits claim plaintiffs who used the drugs suffered severe side effects such as stomach paralysis, bowel obstructions, and vision loss, along with failure-to-warn and misleading marketing
However, limit caffeine to morning and early afternoon to protect sleep quality
[Google Scholar] 19.Bonner Loren
While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]